Sitagliptin and Januvia: Generic Products, Strengths and Prescription Access

Sitagliptin is a prescription medicine used in adults with Type 2 diabetes. Januvia is a branded sitagliptin product. Sitagliptin and Januvia are not over-the-counter medicines in the United States. Current U.S. labels identify both Januvia and generic sitagliptin products as prescription drugs.

This page focuses on product identity and access: what sitagliptin is, how Januvia relates to generic sitagliptin, which tablet strengths are currently labeled, and what a patient may need to verify before a prescription is filled.

Sitagliptin vs Januvia: active ingredient and brand

Sitagliptin is the active drug. Januvia is the brand name for a sitagliptin tablet originally approved in the United States in 2006. It belongs to the dipeptidyl peptidase-4, or DPP-4, inhibitor class and is labeled as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes.

The current Januvia label lists film-coated oral tablets containing 25 mg, 50 mg, or 100 mg of sitagliptin. The label also identifies Januvia as an Rx-only product.

A brand name and an active ingredient are not the same thing. A prescription may identify Januvia specifically, or it may identify sitagliptin in a way that permits dispensing an approved generic product subject to the prescription, state substitution rules, product availability, and payer requirements.

Is generic sitagliptin FDA approved?

Yes. FDA’s 2025 first-generic approvals list records the first approval for a generic sitagliptin phosphate tablet on December 30, 2025, under ANDA 202327, referencing Januvia. FDA also cautions that an approval date does not necessarily mean a product is immediately available in the market.

Current DailyMed records show generic sitagliptin prescription tablets from more than one labeler. For example, Teva Pharmaceuticals has a sitagliptin label under ANDA 202327, and Apotex has a current sitagliptin label under ANDA 202425. These current labels identify oral film-coated tablets corresponding to 25 mg, 50 mg, and 100 mg of sitagliptin.

That means “generic sitagliptin” is now a real FDA-approved product category, not merely a future possibility. For a specific prescription, contact the pharmacy to confirm current product availability, manufacturer options, and coverage.

Strengths and product identity

For current U.S. Januvia and generic sitagliptin products, the commonly labeled strengths are:

• 25 mg tablet
• 50 mg tablet
• 100 mg tablet

Strength should not be selected by comparing retail listings or by assuming that a higher number is appropriate. The prescription and current labeling determine the intended product. Januvia labeling also includes renal-function-based dosage adjustments, which is one reason the exact prescribed strength matters clinically.

When comparing a branded and generic bottle, useful product details include the active ingredient, strength, dosage form, NDC, manufacturer or labeler, and whether the product is an FDA-approved NDA or ANDA product. Tablet color and imprint can differ among manufacturers even when the active ingredient and labeled strength are the same.

Prescription status in the United States

Current Januvia and generic sitagliptin labels are prescription-drug labels. Sitagliptin is not an OTC medicine in the United States. Marketplace listings or overseas seller wording should not be treated as evidence that sitagliptin is legally available without a prescription in the United States.

Cost, formulary and pharmacy access questions

Generic approval can expand product choices, but the lowest-cost option is not automatically the same for every patient. What a patient pays can depend on insurance design, formulary placement, deductible status, pharmacy network, the specific manufacturer available, and whether the prescription is written in a way that permits substitution.

Useful questions before obtaining the medication include:

• Is the prescription for Januvia specifically or for sitagliptin generally?
• Which strength and dosage form are written on the prescription?
• Does the patient’s plan cover the branded product, a generic product, or both?
• Is prior authorization or another coverage requirement involved?
• If the manufacturer changes at refill, is the active ingredient, strength, and dosage form the same as the prescribed product?
• Is the pharmacy checking a current product rather than an old or discontinued listing?

Contact Valencia Town Center Pharmacy to confirm current product availability, manufacturer options, and coverage for a specific prescription.

Sitagliptin in the broader Type 2 diabetes research cluster

Sitagliptin is only one medication option used in Type 2 diabetes. It is distinct from metformin, which is a biguanide, and from semaglutide, which is a GLP-1 receptor agonist. Readers researching how sitagliptin differs from metformin can use our sitagliptin vs metformin comparison. For the broader medication index, see Type 2 Diabetes & Metabolic Medications.

Safety boundary

Sitagliptin labeling contains clinically important warnings and precautions, including pancreatitis, heart failure risk in the DPP-4 inhibitor class, renal-function considerations, serious hypersensitivity reactions, severe joint pain, and bullous pemphigoid. Those issues are reasons to follow the prescription and current labeling rather than choosing a strength or changing therapy based on a product-comparison page.